MedTrace Logo

A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma

NCT06376045 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 317

Last updated 2025-12-11

No results posted yet for this study

Summary

The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.

Conditions

Interventions

DRUG

Rocatinlimab

Rocatinlimab will be administered by SC injection.

DRUG

Placebo

Placebo will be administered by SC injection.

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-24
Primary Completion
2026-10-19
Completion
2026-12-11
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Australia
  • Bulgaria
  • Canada
  • Chile
  • China
  • Colombia
  • Czechia
  • Hong Kong
  • Hungary
  • Japan
  • Mexico
  • Poland
  • Romania
  • South Korea
  • Taiwan
  • Thailand
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06376045 on ClinicalTrials.gov